According to Canadian Blood Services, the demand for immunoglobulin is rising every year, but 70% of Canada’s supply comes from international sources—mostly the U.S.
The loss was mentioned as a single line item in the 2025 public accounts, the audited financial statements of the federal government for the 2024-25 fiscal year.
Procuring lifesaving drugs is a daunting challenge in many low- and middle-income countries. Essential treatments are often neither available nor affordable in these nations, even decades after the drugs entered the market.
